Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02367469 · ClinicalTrials.gov registry record
Tryptophan Metabolism in Human Brain Tumors
A clinical trial, sponsored by Wayne State University.
- Completed
- Registry status
- 105
- Enrollment target
NCT02367469: Completed study, sponsored by Wayne State University.
NCT02367469 is a clinical trial that has completed, run by Wayne State University. The registered enrollment target is 105 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02367469 has completed, sponsored by Wayne State University.
- COMPLETED
- Registry status
- 105 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine the potential clinical utility of PET imaging using the radiotracer \[C-11\]alpha-methyl-L-tryptophan in the diagnosis, differentiation and monitoring of various brain tumors, both before and after initial treatment. We will also study mechanisms and clinical significance of abnormal brain tumor tryptophan metabolism using resected tumor tissues.
Primary Outcome
Diagnostic accuracy of AMT-PET to differentiate brain tumor types and detect tumor infiltration of the brain.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2014-02 |
| Est. Completion | 2021-12-31 |
What the finished NCT02367469 record still lists
NCT02367469 is an observational study that tracks outcomes without assigning an intervention. The registered 105 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02367469 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02367469 about?
NCT02367469 is a clinical study titled "Tryptophan Metabolism in Human Brain Tumors". The main purpose of this study is to determine the potential clinical utility of PET imaging using the radiotracer \[C-11\]alpha-methyl-L-tryptophan in the diagnosis, differentiation and monitoring of various brain tumors, both before and after initial treatment. We will also study mechanisms and cl...
What is the current status of trial NCT02367469?
This trial is currently completed. The enrollment target is 105 participants. The study started on 2014-02. Estimated completion is 2021-12-31.
Who is sponsoring clinical trial NCT02367469?
This trial is sponsored by Wayne State University, which has 163 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03372317 · 105 participants
Tau PET in Imaging and Cognition: Healthy Adults From 55-90
- NCT04253964 · 105 participants · Phase 2
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy
- NCT04742452 · 105 participants · NA
Comparison of Partial Rotator Cuff Repair vs. Superior Capsular Reconstruction for Irreparable Rotator Cuff Tears
- NCT04875429 · 105 participants · NA
Zenith® Fenestrated+ Clinical Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia